Goals: Our aim was to study the prevalence of dysplasia and progression to high-grade dysplasia (HGD) and esophageal adenocarcinoma (EAC) in African Americans (AA) with Barrett's esophagus (BE) and compare it with that of non-Hispanic white (NHW) controls.
(J Clin Gastroenterol 2017;51:402-406) E sophageal adenocarcinoma (EAC) and its precursor, Barrett's esophagus (BE), are predominantly diseases of white men. 1,2 BE is relatively uncommon in African Americans (AA), and thus, sparse data exist regarding the incidence and prevalence rates of BE and BE-related dysplasia in AA. [3] [4] [5] However, recent studies report an increasing incidence of EAC in AA. 6 Although there is an increase in the incidence of EAC in non-Hispanic white (NHW) and AA patients over time, the racial disparities have not changed. An analysis of Surveillance, Epidemiology, and End Results data from 1983 to 2012 show an incidence rate of EAC of 0.5 per 100,000 person-years in AA patients compared with 2.4 in white patients. Also, over the 3 decades, the male-to-female ratio in AA patients with EAC has decreased from 4.81 in 1983 to 1992 to 3.33 from 2003 to 2012. 7 There do not seem to be any racial differences in the prevalence of gastroesophageal reflux disease (GERD)-related symptoms, but the AA cohort has a lower prevalence of reflux esophagitis compared with the NHW cohort. 3, 8 Although substantial evidence exists to support the lower prevalence of BE in AA patients, a few studies reported no significant racial differences in BE. In a US study of 4457 patients who underwent upper endoscopy, no significant racial differences were observed in the prevalence of BE, irrespective of GERD symptoms. 9 In another study based on a veteran population, the race was not a predictor for the presence of BE. 10 In addition, the prevalence of dysplasia in AA patients with BE also seems to be lower compared with that in NHW patients with BE. Khoury et al 11 performed a singlecenter, retrospective analysis of 16 AA BE cases and 95 NHW BE cases, reporting that AA patients were less likely to have dysplastic BE (0% vs. 7%). In a recent study of 35 AA patients with BE, none of the patients had dysplasia as compared with 5.6% in the NHW cohort (P = 0.06). 4 Once in a surveillance program, it is unknown whether AA patients with BE are at the same risk for progression to dysplasia/EAC as NHW patients. There are limited data about the disease course and the incidence of dysplasia and EAC in AA patients with BE. 12, 13 Hence, our aim was to (1) estimate the prevalence of dysplasia in AA patients with BE compared with NHW patients with BE and (2) assess the influence of race in the progression to high-grade dysplasia (HGD) and EAC in BE. We hypothesized that there is a lower prevalence of dysplasia and EAC in AA patients with BE compared with their NHW counterparts and that AA patients with BE are at a lower risk of developing HGD/ EAC under surveillance.
MATERIALS AND METHODS

Study Population
After approval by the institutional review board, the patient population for the study was obtained from the prospectively collected Barrett's registry at Cleveland Clinic. This database includes BE patients seen in the department of Gastroenterology since 1979. In this study, all AA and NHW patients with BE who were seen between January 2002 and December 2013 were included. Patients of unknown race and races other than NHW or AA were excluded. Age, gender, medication such as proton-pump inhibitors (PPI), histamine receptor antagonists (H2RA), aspirin and nonsteroidal anti-inflammatory drug use, the body mass index (BMI), the date of endoscopy, the length of the BE segment, the size of hiatal hernia, and histologic findings were reviewed.
Patients were considered to have BE if there is a salmon-colored mucosa of any length on endoscopy with intestinal metaplasia was present on biopsy. The distance from the proximal end of the gastric folds to the squamocolumnar junction was calculated as the BE length. Biopsy results were read as no dysplasia, low-grade dysplasia (LGD), indefinite for dysplasia, HGD, and EAC as per the Vienna classification. 14 Indefinite for dysplasia was included under LGD as they share similar clinical management. The surveillance intervals varied depending on the presence of dysplasia and as per existing guidelines for BE surveillance. 15 For nondysplastic BE, endoscopy was repeated in 1 year to confirm the absence of dysplasia and every 3 years thereafter. Since 2011, the surveillance interval was extended to 3 to 5 years. For LGD, the surveillance biopsy protocol consisted of 4-quadrant biopsies every 1 to 2 cm of the BE with standard or jumbo biopsy forceps every 6 to 12 months. Patients with HGD were referred for esophagectomy or endoscopic eradication therapy depending on the year of diagnosis and their surgical candidacy. In most cases of dysplasia or EAC, the diagnosis was confirmed by a gastrointestinal pathologist or reviewed at a consensus conference. Progression to LGD, HGD, or EAC was evaluated during the follow-up. The follow-up time was defined as months from the first endoscopy to progression or to the last endoscopy if there was no progression. Patients who had dysplasia or EAC at the initial endoscopy or within 1 year were considered as prevalence cases, and patients who developed LGD/HGD/EAC after at least 1 year of follow-up were considered as incident cases.
Statistical Analysis
Data are presented as mean ± SD, median (25th, 75th percentiles), or frequency (percent). To assess the differences between the groups, a univariable analysis was performed. Analysis of variance or nonparametric KruskalWallis tests were used for continuous factors and Pearson w 2 or Fisher exact tests were used for categorical variables.
A time-to-event analysis was performed to assess the association between the race and progression in the subgroup of patients without HGD or EAC at baseline. Follow-up was truncated at 3 years as 50% of the individuals were followed for <3 years after the baseline EGD. Kaplan-Meier plots were constructed and log-rank tests were used to compare groups. A P < 0.05 was considered to be statistically significant. SAS version 9.4 (The SAS Institute, Cary, NC) was used to perform all analyses.
RESULTS
The total study population consisted of 2544 patients (Fig. 1) . The racial distribution was as follows: NHW 2394 (94%), AA 52 (2%), Hispanic 18 (0.70%), Asian 4 (0.15%), American Indian 4 (0.15%), multiracial 5 (0.19%), and unknown/others 67(2.63%). A total of 2446 individuals were included in our analysis. The average age was 60 ± 13 years and 75% were men. Table 1 presents a description of patient characteristics. In comparison with NHW patients, AA patients with BE were more likely to be women and less likely to use PPIs. There was a trend toward a higher prevalence of nondysplastic BE in the AA compared with the NHW cohort, with 42 (80.8%) patients in the AA against 1638 (68.4%) in the NHW cohort (P = 0.058).
Among 2446 patients, 501 had HGD/EAC on the first endoscopy and 42 developed HGD/EAC within 1 year. About 892 patients did not have any surveillance information available. Therefore, a total of 1011 patients (20 AA and 991 NHW) constituted the surveillance cohort and were included in the progression analysis ( Table 2 ). The median follow-up time was 43 months (range, 21 to 81 mo). During this time, 19% of the patients had progression of dysplasia. About 134 NHW and 2 AA patients who had no dysplasia progressed to LGD; 20 NHW patients progressed from no dysplasia to HGD; 15 NHW and 1 AA patient with no dysplasia progressed to cancer; 16 NHW patients progressed from LGD to HGD; and 3 NHW patients from LGD to cancer (Fig. 2) . There was no evidence to suggest that the race was associated with progression to dysplasia in either patients without dysplasia or LGD at baseline (Fig. 3) . Because of the low number of AA patients who progressed (n = 3), a multivariable analysis stratified by baseline dysplasia could not be performed. After adjusting for gender for any progression in all the patients, the race remained nonsignificant.
Twelve of 20 (60%) patients were women in the AA surveillance cohort, whereas 275/991 (27.7%) were women in the NHW cohort. There were no significant differences in the age, the BMI, the BE segment length, the hiatal hernia size, medication use, or progression to HGD/EAC between the AA and the NHW surveillance cohorts (Table 2) .
DISCUSSION
As per the US Census Bureau, AA comprise 12.6% of the total population of the United States and 10.4% of the total population in the Midwest. 16 In our Barrett's registry, only 5% of the patients were AA, suggesting a low prevalence of Barrett's in this population. Since 1980s, numerous studies have reported the preponderance of BE with EAC in NHW men and its rarity in the AA population. 4, 11, 17, 18 Whether this is due to genetic differences leading to a protective phenotype or racial differences in the risk factors for BE is not entirely clear. The genetic factors to account for this racial disparity are the focus of intense investigation, but none have been identified so far. A factor that is worth bearing scrutiny is the higher prevalence of Helicobacter pylori infection in black as compared with NHW patients. In a US study on 7465 adults, the age-adjusted prevalence for H. pylori was substantially higher among AA (52.7%) than among NHW (26.2%) individuals. 19 Chronic gastritis from H. pylori leads to gastric atrophy and the subsequent reduced gastric acid production translates into a lower risk of BE. Supporting evidence comes from a recent meta-analysis, which showed that H. pylori infection leads to a reduced risk of BE [relative risk, 0.46; 95% confidence interval (CI), 0.40-0.53]. 20 A recent study based on a VA population highlighted the racial differences in risk factors for BE. However, in this study, H. pylori negativity and a high-waist hip ratio was predictive of BE in NHW, but not in AA individuals. In AA, the risk factors for BE included a hiatus hernia Z3 cm [odds ratio (OR), LGD, low-grade dysplasia; NHW, non-Hispanic whites; NSAID, nonsteroidal anti-inflammatory drugs; PPI, proton-pump inhibitors.
4.12; 95% CI, 1.57-10.81] and a history of GERD or PPI use (OR, 3.70; 95% CI, 1.40-9.78), whereas in NHW, a high-waist hip ratio (OR, 2.82; 95% CI, 1.41-5.63), hiatus hernia Z3 cm (OR, 4.95; 95% CI, 3.05-8.03), PPI use (OR, 1.88; 95% CI, 1.33-2.66), and H. pylori (OR, 0.64; 95% CI, 0.41-0.99) were associated with BE risk. 4 A significant finding of our study is the attenuation of gender disparity in the AA compared with the NHW group. Inspite of the genetic protection conferred by the race, AA women comprised 46% of the total AA patients with BE compared with 25% of NHW women. In other words, the female-to-male ratio was 1: 1.13 in AA compared with 1:3 in NHW patients. These findings support a joint gender and race interaction in the development of BE. One explanation for these findings could be a higher genetic load of susceptibility alleles in women in the admixed AA population. Prior studies of BE in AA individuals reported small numbers of patients, and hence a meaningful interpretation regarding gender differences could not be achieved. 4, 21, 22 Another explanation for this finding in our study may be racial and gender differences in the BMI or adipokines. AA women have the highest rates of obesity in the United States: nearly 59%, compared with 33% in NHW women. 23, 24 An increased BMI seems to be a risk factor for BE in women. 19 As AA women are known to have an increased BMI in comparison with their NHW counterparts, 25, 26 it is conceivable that AA women are more predisposed to BE than NHW women. In our study, there were no significant differences in the BMI, which raises the possibility of adiopkines. Adipokines such as adiponectin and leptin may influence the association between visceral obesity and BE. High levels of leptin are associated with a 2-fold increased risk of BE, 27 whereas adiponectin seems to have a protective effect, at least in some studies. 28 Leptin levels are known to be higher in women than in men after adjusting for the total body fat. 29 Among women, racial differences persist in adipokine levels. AA women have lower total adiponectin (b, À3.40; 95% CI, À4.29 to À2.52; P < 0.001) and higher leptin levels (b, 3.26; 95% CI, 1.36-5.16; P < 0.001) compared with NHW women. 30 These factors may account for the gender attenuation we noted in AA women with BE.
In our study, the prevalence of nondysplastic BE was 68.4% in the NHW group compared with 80.8% in AA group. This is in accordance with previous studies, which showed a lower prevalence of dysplasia in AA patients with BE. In a study on 95 NHW and 16 AA patients with BE, AAs were less likely to have dysplasia (0% vs. 7%,) and had less frequent long-segment BE (12% vs. 26%). 11 In another study on 35 AA patients with BE, none of them had dysplasia as compared with 251 NHW patients with BE (236 no dysplasia, 13 LGD, and 2 HGD; P = 0.06). 4 Similarly, the incidence rates of EAC are also lower in AA compared with NHW. In a large veterans cohort with BE (n = 29,536), the incidence rate of EAC in the AA cohort was 2.62 per 1000 person-years compared with 3.34 in the NHW cohort, with an incidence rate ratio of 0.78, suggesting a lower risk of progression. 13 In our study, we did not find any racial differences in the progression to HGD/ EAC, possibly due to the small number of participants and the short duration of follow-up.
The main strength of this study was that it included a large number of AA patients with confirmed BE, that is intestinal metaplasia. Surveillance information was available, which allowed us to assess for the risk of progression to HGD/EAC. Most of the cases of suspected dysplasia or cancer were confirmed by a gastrointestinal pathologist or reviewed at a consensus conference, thereby reducing the interobserver variability.
Our study has several limitations. As this was not a population-based study, there may be a referral bias. Such a bias alone, however, would not explain the large racial differences found in our study. BMI values were missing for several patients, which may impact the study findings. Nonetheless, it is the visceral adiposity or the waist-hip ratio that is associated with the risk of BE than BMI per se. The other limitation is the lack of information about the H. pylori status in our study population. Finally, the finding of a higher proportion of AA women with BE may be due to gender differences in the health-seeking behavior among AA individuals. AA women are significantly more likely to seek professional help and utilize physician services than AA men. 31 In conclusion, the male-to-female gender ratio is attenuated in AA patients with BE compared with their NHW counterparts. There is a lower prevalence of BEassociated neoplasia in AA compared with NHW patients. Genetic factors and environmental factors contributing to this disparity require further study.
